Selective Late-Timepoint 68Ga-PSMA-11 PET/CT in Prostate Cancer: A Management-Focused Framework
Cancers · 19.11.2026 · 18 (22) · 3703
DOI: 10.3390/cancers18223703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 19.11.2026. Verfasst von Munir Ghesani und 3 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Telix Pharmaceuticals.
Abstract (Originalsprache)
68Ga-PSMA-11 PET/CT has the most established evidence base among PSMA-targeted imaging agents for prostate cancer and is incorporated into clinical guidelines internationally for initial staging, prostate-specific antigen (PSA) persistence, biochemical recurrence (BCR), and selection for PSMA-directed therapy. Its integration into routine clinical practice reflects established acquisition workflows and consistently high diagnostic performance, including localization of small-volume nodal and distant disease that may be occult on conventional imaging. Imaging is generally performed approximately 60 min after 68Ga-PSMA-11 administration; however, interest in additional image acquisition at a later timepoint (i.e., late-timepoint imaging) has emerged, with evidence from published studies and real-world experience from centers of excellence supporting feasibility and utility for select clinical scenarios. This additional late (generally 90 min to 3 h) acquisition may improve lesion-to-background contrast or help characterize low-level uptake, indeterminate findings, and suspected recurrence adjacent to physiologic urinary activity. However, improved contrast or lesion detection does not consistently translate into changes in clinical management, supporting selective rather than routine use. In this narrative review, we synthesize published evidence and expert clinical experience to define the potential role of late-timepoint 68Ga-PSMA-11 PET/CT. We position late-timepoint imaging as a selective, management-focused strategy that can provide complementary information when the standard acquisition leaves a clinically actionable question unresolved. The highest-value applications include early BCR with uncertain local-only versus local-plus-regional nodal recurrence, indeterminate pelvic or metastatic uptake, and suspected local recurrence adjacent to physiologic urinary activity. In appropriately selected cases, a late acquisition may be readily integrated into the established PET workflow using the same imaging system and acquisition framework, enabling patient-specific temporal or postvoid information to refine staging and support individualized treatment planning. We propose a management-anchored framework and practical workflow, based on published literature and clinical experience, to support selective, operationally feasible, and patient-centered use.
Förderung
- Telix Pharmaceuticals
Zitieren
APA
Ghesani, M., Herrmann, K., Yeh, R., & Fanti, S. (2026). Selective Late-Timepoint 68Ga-PSMA-11 PET/CT in Prostate Cancer: A Management-Focused Framework. Cancers, 18(22), 3703. https://doi.org/10.3390/cancers18223703
Vancouver
Ghesani M, Herrmann K, Yeh R, Fanti S. Selective Late-Timepoint 68Ga-PSMA-11 PET/CT in Prostate Cancer: A Management-Focused Framework. Cancers. 2026;18(22):3703. doi:10.3390/cancers18223703
BibTeX
@article{Ghesani2026,
author = {Ghesani, Munir and Herrmann, Ken and Yeh, Randy and Fanti, Stefano},
title = {Selective Late-Timepoint 68Ga-PSMA-11 PET/CT in Prostate Cancer: A Management-Focused Framework},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3703},
doi = {10.3390/cancers18223703}
}
EUVIMED